first-line pharmacotherapy obesity
Stop Calling GLP-1's Lifestyle Drugs - Semaglutide Won
Semaglutide is now recognized as first-line pharmacotherapy for obesity, and in 2023 it ranked as the 157th most prescribed medication in the United States with over 3 million prescriptions. The American College of Physicians (ACP) has officially labeled it a core treatment, ending the myth that it is merely a